Reykjavik, Iceland
Went public on 7/18/2000 at $18 per share
Filing Range: 9.6 mil. shares @ $14 to $18
Shares Outstanding: 41.4 mil. shares
Underwriters: Morgan Stanley Dean Witter/Lehman Brothers
Company Counsel: Smith Stratton Wise Heher & Brennan
Manager Counsel: Davis Polk & Wardwell
Auditor: PricewaterhouseCoopers
The Company:
Operates a genomics company that uses human genetics to acquire new knowledge amount health and disease and using it in pharmaceutical development.
Venture Backers:
Burr, Egan, Deleage & Co.
Alta Communications
Atlas Venture
Advent International Corp.
HarbourVest Partners LLC
ARCH Venture Partners
Medical Science Partners
Polaris Venture Partners
Financing Rounds:
Number of Round Amt.
Round # Round Date Stage Investors ($ thousands)
1 08/01/1996 1 Expansion 736.0
2 09/12/1997 2 Later Stage 334.0
3 10/17/1997 8 Early Stage 3961.2
4 03/01/1998 1 Expansion 9275.0
6 03/30/1999 1 Expansion 825.0
7 08/08/1999 1 Later Stage 37500.0
Financials:
(Data in $ millions)
Y/E
12/31/99
Total Revenues: $16.4
Net Income: -23.2